At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab in the Treatment of Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating bevacizumab, oxaliplatin, and 1 other intervention for Colorectal Cancer. Completed, enrolled 50 participants.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving capecitabine and oxaliplatin together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving oxaliplatin and capecitabine together with bevacizumab works in treating patients with metastatic or recurrent colorectal cancer.
Study Details
Timeline
Interventions
10 mg/kg intravenously over 30-90 minutes on day 1
85 mg/m2 intravenously over 2 hours on day 1.
Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort